Request for Covid-19 Impact Assessment of this Report

Pharmaceuticals

Europe Anti-angiogenic Agent Market Report 2016

  • QYR827039
  • 100 Pages
  • December 2016
  • Pharmaceuticals
Download Sample    Get Discount   
 
Notes:

Sales, means the sales volume of Anti-angiogenic Agent

Revenue, means the sales value of Anti-angiogenic Agent

This report studies sales (consumption) of Anti-angiogenic Agent in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering

Pfizer, Inc. (US)

Eli Lilly and Company (USA)

Bayer HealthCare Pharmaceuticals, Inc. (USA)

Abbott Laboratories (USA)

AstraZeneca Plc. (UK)

Meditrina Pharmaceuticals, Inc. (US)

Neurocrine Biosciences, Inc. (US)

AEterna Zentaris, Inc. (Canada)

Market Segment by Countries, this report splits Europe into several key Countries, with sales (consumption), revenue, market share and growth rate of Anti-angiogenic Agent in these countries, from 2011 to 2021 (forecast), like

Germany

France

UK

Russia

Italy

Spain

Benelux

Split by product type, with sales, revenue, price, market share and growth rate of each type, can be divided into

Type I

Type II

Type III

Split by application, this report focuses on sales, market share and growth rate of Anti-angiogenic Agent in each application, can be divided into

Application 1

Application 2

Application 3

Table of Contents

Europe Anti-angiogenic Agent Market Report 2016

1 Anti-angiogenic Agent Overview

1.1 Product Overview and Scope of Anti-angiogenic Agent

1.2 Classification of Anti-angiogenic Agent

1.2.1 Type I

1.2.2 Type II

1.2.3 Type III

1.3 Application of Anti-angiogenic Agent

1.3.1 Application 1

1.3.2 Application 2

1.3.3 Application 3

1.4 Anti-angiogenic Agent Market by Countries

1.4.1 Germany Status and Prospect (2011-2021)

1.4.2 France Status and Prospect (2011-2021)

1.4.3 UK Status and Prospect (2011-2021)

1.4.4 Russia Status and Prospect (2011-2021)

1.4.5 Italy Status and Prospect (2011-2021)

1.4.6 Spain Status and Prospect (2011-2021)

1.4.7 Benelux Status and Prospect (2011-2021)

1.5 Europe Market Size (Value and Volume) of Anti-angiogenic Agent (2011-2021)

1.5.1 Europe Anti-angiogenic Agent Sales and Growth Rate (2011-2021)

1.5.2 Europe Anti-angiogenic Agent Revenue and Growth Rate (2011-2021)

2 Europe Anti-angiogenic Agent by Manufacturers, Type and Application

2.1 Europe Anti-angiogenic Agent Market Competition by Manufacturers

2.1.1 Europe Anti-angiogenic Agent Sales and Market Share of Key Manufacturers (2015 and 2016)

2.1.2 Europe Anti-angiogenic Agent Revenue and Share by Manufacturers (2015 and 2016)

2.2 Europe Anti-angiogenic Agent (Volume and Value) by Type

2.2.1 Europe Anti-angiogenic Agent Sales and Market Share by Type (2011-2016)

2.2.2 Europe Anti-angiogenic Agent Revenue and Market Share by Type (2011-2016)

2.3 Europe Anti-angiogenic Agent (Volume and Value) by Countries

2.3.1 Europe Anti-angiogenic Agent Sales and Market Share by Countries (2011-2016)

2.3.2 Europe Anti-angiogenic Agent Revenue and Market Share by Countries (2011-2016)

2.4 Europe Anti-angiogenic Agent (Volume) by Application

3 Germany Anti-angiogenic Agent (Volume, Value and Sales Price)

3.1 Germany Anti-angiogenic Agent Sales and Value (2011-2016)

3.1.1 Germany Anti-angiogenic Agent Sales and Growth Rate (2011-2016)

3.1.2 Germany Anti-angiogenic Agent Revenue and Growth Rate (2011-2016)

3.1.3 Germany Anti-angiogenic Agent Sales Price Trend (2011-2016)

3.2 Germany Anti-angiogenic Agent Sales and Market Share by Manufacturers

3.3 Germany Anti-angiogenic Agent Sales and Market Share by Type

3.4 Germany Anti-angiogenic Agent Sales and Market Share by Application

4 France Anti-angiogenic Agent (Volume, Value and Sales Price)

4.1 France Anti-angiogenic Agent Sales and Value (2011-2016)

4.1.1 France Anti-angiogenic Agent Sales and Growth Rate (2011-2016)

4.1.2 France Anti-angiogenic Agent Revenue and Growth Rate (2011-2016)

4.1.4 France Anti-angiogenic Agent Sales Price Trend (2011-2016)

4.2 France Anti-angiogenic Agent Sales and Market Share by Manufacturers

4.3 France Anti-angiogenic Agent Sales and Market Share by Type

4.4 France Anti-angiogenic Agent Sales and Market Share by Application

5 UK Anti-angiogenic Agent (Volume, Value and Sales Price)

5.1 UK Anti-angiogenic Agent Sales and Value (2011-2016)

5.1.1 UK Anti-angiogenic Agent Sales and Growth Rate (2011-2016)

5.1.2 UK Anti-angiogenic Agent Revenue and Growth Rate (2011-2016)

5.1.5 UK Anti-angiogenic Agent Sales Price Trend (2011-2016)

5.2 UK Anti-angiogenic Agent Sales and Market Share by Manufacturers

5.3 UK Anti-angiogenic Agent Sales and Market Share by Type

5.4 UK Anti-angiogenic Agent Sales and Market Share by Application

6 Russia Anti-angiogenic Agent (Volume, Value and Sales Price)

6.1 Russia Anti-angiogenic Agent Sales and Value (2011-2016)

6.1.1 Russia Anti-angiogenic Agent Sales and Growth Rate (2011-2016)

6.1.2 Russia Anti-angiogenic Agent Revenue and Growth Rate (2011-2016)

6.1.6 Russia Anti-angiogenic Agent Sales Price Trend (2011-2016)

6.2 Russia Anti-angiogenic Agent Sales and Market Share by Manufacturers

6.3 Russia Anti-angiogenic Agent Sales and Market Share by Type

6.4 Russia Anti-angiogenic Agent Sales and Market Share by Application

7 Italy Anti-angiogenic Agent (Volume, Value and Sales Price)

7.1 Italy Anti-angiogenic Agent Sales and Value (2011-2016)

7.1.1 Italy Anti-angiogenic Agent Sales and Growth Rate (2011-2016)

7.1.2 Italy Anti-angiogenic Agent Revenue and Growth Rate (2011-2016)

7.1.7 Italy Anti-angiogenic Agent Sales Price Trend (2011-2016)

7.2 Italy Anti-angiogenic Agent Sales and Market Share by Manufacturers

7.3 Italy Anti-angiogenic Agent Sales and Market Share by Type

7.4 Italy Anti-angiogenic Agent Sales and Market Share by Application

8 Spain Anti-angiogenic Agent (Volume, Value and Sales Price)

8.1 Spain Anti-angiogenic Agent Sales and Value (2011-2016)

8.1.1 Spain Anti-angiogenic Agent Sales and Growth Rate (2011-2016)

8.1.2 Spain Anti-angiogenic Agent Revenue and Growth Rate (2011-2016)

8.1.8 Spain Anti-angiogenic Agent Sales Price Trend (2011-2016)

8.2 Spain Anti-angiogenic Agent Sales and Market Share by Manufacturers

8.3 Spain Anti-angiogenic Agent Sales and Market Share by Type

8.4 Spain Anti-angiogenic Agent Sales and Market Share by Application

9 Benelux Anti-angiogenic Agent (Volume, Value and Sales Price)

9.1 Benelux Anti-angiogenic Agent Sales and Value (2011-2016)

9.1.1 Benelux Anti-angiogenic Agent Sales and Growth Rate (2011-2016)

9.1.2 Benelux Anti-angiogenic Agent Revenue and Growth Rate (2011-2016)

9.1.9 Benelux Anti-angiogenic Agent Sales Price Trend (2011-2016)

9.2 Benelux Anti-angiogenic Agent Sales and Market Share by Manufacturers

9.3 Benelux Anti-angiogenic Agent Sales and Market Share by Type

9.4 Benelux Anti-angiogenic Agent Sales and Market Share by Application

10 Europe Anti-angiogenic Agent Manufacturers Analysis

10.1 Pfizer, Inc. (US)

10.1.1 Company Basic Information, Manufacturing Base and Competitors

10.1.2 Anti-angiogenic Agent Product Type, Application and Specification

10.1.2.1 Type I

10.1.2.2 Type II

10.1.3 Pfizer, Inc. (US) Anti-angiogenic Agent Sales, Revenue, Price and Gross Margin (2011-2016)

10.1.4 Main Business/Business Overview

10.2 Eli Lilly and Company (USA)

10.2.1 Company Basic Information, Manufacturing Base and Competitors

10.2.2 Anti-angiogenic Agent Product Type, Application and Specification

10.2.2.1 Type I

10.2.2.2 Type II

10.2.3 Eli Lilly and Company (USA) Anti-angiogenic Agent Sales, Revenue, Price and Gross Margin (2011-2016)

10.2.4 Main Business/Business Overview

10.3 Bayer HealthCare Pharmaceuticals, Inc. (USA)

10.3.1 Company Basic Information, Manufacturing Base and Competitors

10.3.2 Anti-angiogenic Agent Product Type, Application and Specification

10.3.2.1 Type I

10.3.2.2 Type II

10.3.3 Bayer HealthCare Pharmaceuticals, Inc. (USA) Anti-angiogenic Agent Sales, Revenue, Price and Gross Margin (2011-2016)

10.3.4 Main Business/Business Overview

10.4 Abbott Laboratories (USA)

10.4.1 Company Basic Information, Manufacturing Base and Competitors

10.4.2 Anti-angiogenic Agent Product Type, Application and Specification

10.4.2.1 Type I

10.4.2.2 Type II

10.4.3 Abbott Laboratories (USA) Anti-angiogenic Agent Sales, Revenue, Price and Gross Margin (2011-2016)

10.4.4 Main Business/Business Overview

10.5 AstraZeneca Plc. (UK)

10.5.1 Company Basic Information, Manufacturing Base and Competitors

10.5.2 Anti-angiogenic Agent Product Type, Application and Specification

10.5.2.1 Type I

10.5.2.2 Type II

10.5.3 AstraZeneca Plc. (UK) Anti-angiogenic Agent Sales, Revenue, Price and Gross Margin (2011-2016)

10.5.4 Main Business/Business Overview

10.6 Meditrina Pharmaceuticals, Inc. (US)

10.6.1 Company Basic Information, Manufacturing Base and Competitors

10.6.2 Anti-angiogenic Agent Product Type, Application and Specification

10.6.2.1 Type I

10.6.2.2 Type II

10.6.3 Meditrina Pharmaceuticals, Inc. (US) Anti-angiogenic Agent Sales, Revenue, Price and Gross Margin (2011-2016)

10.6.4 Main Business/Business Overview

10.7 Neurocrine Biosciences, Inc. (US)

10.7.1 Company Basic Information, Manufacturing Base and Competitors

10.7.2 Anti-angiogenic Agent Product Type, Application and Specification

10.7.2.1 Type I

10.7.2.2 Type II

10.7.3 Neurocrine Biosciences, Inc. (US) Anti-angiogenic Agent Sales, Revenue, Price and Gross Margin (2011-2016)

10.7.4 Main Business/Business Overview

10.8 AEterna Zentaris, Inc. (Canada)

10.8.1 Company Basic Information, Manufacturing Base and Competitors

10.8.2 Anti-angiogenic Agent Product Type, Application and Specification

10.8.2.1 Type I

10.8.2.2 Type II

10.8.3 AEterna Zentaris, Inc. (Canada) Anti-angiogenic Agent Sales, Revenue, Price and Gross Margin (2011-2016)

10.8.4 Main Business/Business Overview

11 Anti-angiogenic Agent Manufacturing Cost Analysis

11.1 Anti-angiogenic Agent Key Raw Materials Analysis

11.1.1 Key Raw Materials

11.1.2 Price Trend of Key Raw Materials

11.1.3 Key Suppliers of Raw Materials

11.1.4 Market Concentration Rate of Raw Materials

11.2 Proportion of Manufacturing Cost Structure

11.2.1 Raw Materials

11.2.2 Labor Cost

11.2.3 Manufacturing Expenses

11.3 Manufacturing Process Analysis of Anti-angiogenic Agent

12 Industrial Chain, Sourcing Strategy and Downstream Buyers

12.1 Anti-angiogenic Agent Industrial Chain Analysis

12.2 Upstream Raw Materials Sourcing

12.3 Raw Materials Sources of Anti-angiogenic Agent Major Manufacturers in 2015

12.4 Downstream Buyers

13 Marketing Strategy Analysis, Distributors/Traders

13.1 Marketing Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Development Trend

13.2 Market Positioning

13.2.1 Pricing Strategy

13.2.2 Brand Strategy

13.2.3 Target Client

13.3 Distributors/Traders List

14 Europe Anti-angiogenic Agent Market Forecast (2016-2021)

14.1 Germany Anti-angiogenic Agent Sales Forecast (2016-2021)

14.2 France Anti-angiogenic Agent Sales Forecast (2016-2021)

14.3 UK Anti-angiogenic Agent Sales Forecast (2016-2021)

14.4 Russia Anti-angiogenic Agent Sales Forecast (2016-2021)

14.5 Italy Anti-angiogenic Agent Sales Forecast (2016-2021)

14.6 Spain Anti-angiogenic Agent Sales Forecast (2016-2021)

14.7 Benelux Anti-angiogenic Agent Sales Forecast (2016-2021)

14.8 Europe Anti-angiogenic Agent Sales Forecast by Type (2016-2021)

14.9 Europe Anti-angiogenic Agent Sales Forecast by Application (2016-2021)

15 Research Findings and Conclusion

16 Appendix

Disclosure Section

Research Methodology

Data Source

Disclaimer

List of Tables and Figures

Figure Picture of Anti-angiogenic Agent

Table Classification of Anti-angiogenic Agent

Figure Europe Sales Market Share of Anti-angiogenic Agent by Type in 2015

Figure Type I Picture

Figure Type II Picture

Table Application of Anti-angiogenic Agent

Figure Europe Sales Market Share of Anti-angiogenic Agent by Application in 2015

Figure Application 1 Examples

Figure Application 2 Examples

Figure Germany Anti-angiogenic Agent Revenue and Growth Rate (2011-2021)

Figure France Anti-angiogenic Agent Revenue and Growth Rate (2011-2021)

Figure UK Anti-angiogenic Agent Revenue and Growth Rate (2011-2021)

Figure Russia Anti-angiogenic Agent Revenue and Growth Rate (2011-2021)

Figure Italy Anti-angiogenic Agent Revenue and Growth Rate (2011-2021)

Figure Spain Anti-angiogenic Agent Revenue and Growth Rate (2011-2021)

Figure Benelux Anti-angiogenic Agent Revenue and Growth Rate (2011-2021)

Figure Europe Anti-angiogenic Agent Sales and Growth Rate (2011-2021)

Figure Europe Anti-angiogenic Agent Revenue and Growth Rate (2011-2021)

Table Europe Anti-angiogenic Agent Sales of Key Manufacturers (2015 and 2016)

Table Europe Anti-angiogenic Agent Sales Share by Manufacturers (2015 and 2016)

Figure 2015 Anti-angiogenic Agent Sales Share by Manufacturers

Figure 2016 Anti-angiogenic Agent Sales Share by Manufacturers

Table Europe Anti-angiogenic Agent Revenue by Manufacturers (2015 and 2016)

Table Europe Anti-angiogenic Agent Revenue Share by Manufacturers (2015 and 2016)

Table 2015 Europe Anti-angiogenic Agent Revenue Share by Manufacturers

Table 2016 Europe Anti-angiogenic Agent Revenue Share by Manufacturers

Table Europe Anti-angiogenic Agent Sales and Market Share by Type (2011-2016)

Table Europe Anti-angiogenic Agent Sales Share by Type (2011-2016)

Figure Sales Market Share of Anti-angiogenic Agent by Type (2011-2016)

Figure Europe Anti-angiogenic Agent Sales Growth Rate by Type (2011-2016)

Table Europe Anti-angiogenic Agent Revenue and Market Share by Type (2011-2016)

Table Europe Anti-angiogenic Agent Revenue Share by Type (2011-2016)

Figure Revenue Market Share of Anti-angiogenic Agent by Type (2011-2016)

Figure Europe Anti-angiogenic Agent Revenue Growth Rate by Type (2011-2016)

Table Europe Anti-angiogenic Agent Sales and Market Share by Countries (2011-2016)

Table Europe Anti-angiogenic Agent Sales Share by Countries (2011-2016)

Figure Sales Market Share of Anti-angiogenic Agent by Countries (2011-2016)

Table Europe Anti-angiogenic Agent Revenue and Market Share by Countries (2011-2016)

Table Europe Anti-angiogenic Agent Revenue Share by Countries (2011-2016)

Figure Revenue Market Share of Anti-angiogenic Agent by Countries (2011-2016)

Table Europe Anti-angiogenic Agent Sales and Market Share by Application (2011-2016)

Table Europe Anti-angiogenic Agent Sales Share by Application (2011-2016)

Figure Sales Market Share of Anti-angiogenic Agent by Application (2011-2016)

Figure Germany Anti-angiogenic Agent Sales and Growth Rate (2011-2016)

Figure Germany Anti-angiogenic Agent Revenue and Growth Rate (2011-2016)

Figure Germany Anti-angiogenic Agent Sales Price Trend (2011-2016)

Table Germany Anti-angiogenic Agent Sales by Manufacturers (2015 and 2016)

Table Germany Anti-angiogenic Agent Market Share by Manufacturers (2015 and 2016)

Table Germany Anti-angiogenic Agent Sales by Type (2015 and 2016)

Table Germany Anti-angiogenic Agent Market Share by Type (2015 and 2016)

Table Germany Anti-angiogenic Agent Sales by Application (2015 and 2016)

Table Germany Anti-angiogenic Agent Market Share by Application (2015 and 2016)

Figure France Anti-angiogenic Agent Sales and Growth Rate (2011-2016)

Figure France Anti-angiogenic Agent Revenue and Growth Rate (2011-2016)

Figure France Anti-angiogenic Agent Sales Price Trend (2011-2016)

Table France Anti-angiogenic Agent Sales by Manufacturers (2015 and 2016)

Table France Anti-angiogenic Agent Market Share by Manufacturers (2015 and 2016)

Table France Anti-angiogenic Agent Sales by Type (2015 and 2016)

Table France Anti-angiogenic Agent Market Share by Type (2015 and 2016)

Table France Anti-angiogenic Agent Sales by Application (2015 and 2016)

Table France Anti-angiogenic Agent Market Share by Application (2015 and 2016)

Figure UK Anti-angiogenic Agent Sales and Growth Rate (2011-2016)

Figure UK Anti-angiogenic Agent Revenue and Growth Rate (2011-2016)

Figure UK Anti-angiogenic Agent Sales Price Trend (2011-2016)

Table UK Anti-angiogenic Agent Sales by Manufacturers (2015 and 2016)

Table UK Anti-angiogenic Agent Market Share by Manufacturers (2015 and 2016)

Table UK Anti-angiogenic Agent Sales by Type (2015 and 2016)

Table UK Anti-angiogenic Agent Market Share by Type (2015 and 2016)

Table UK Anti-angiogenic Agent Sales by Application (2015 and 2016)

Table UK Anti-angiogenic Agent Market Share by Application (2015 and 2016)

Figure Russia Anti-angiogenic Agent Sales and Growth Rate (2011-2016)

Figure Russia Anti-angiogenic Agent Revenue and Growth Rate (2011-2016)

Figure Russia Anti-angiogenic Agent Sales Price Trend (2011-2016)

Table Russia Anti-angiogenic Agent Sales by Manufacturers (2015 and 2016)

Table Russia Anti-angiogenic Agent Market Share by Manufacturers (2015 and 2016)

Table Russia Anti-angiogenic Agent Sales by Type (2015 and 2016)

Table Russia Anti-angiogenic Agent Market Share by Type (2015 and 2016)

Table Russia Anti-angiogenic Agent Sales by Application (2015 and 2016)

Table Russia Anti-angiogenic Agent Market Share by Application (2015 and 2016)

Figure Italy Anti-angiogenic Agent Sales and Growth Rate (2011-2016)

Figure Italy Anti-angiogenic Agent Revenue and Growth Rate (2011-2016)

Figure Italy Anti-angiogenic Agent Sales Price Trend (2011-2016)

Table Italy Anti-angiogenic Agent Sales by Manufacturers (2015 and 2016)

Table Italy Anti-angiogenic Agent Market Share by Manufacturers (2015 and 2016)

Table Italy Anti-angiogenic Agent Sales by Type (2015 and 2016)

Table Italy Anti-angiogenic Agent Market Share by Type (2015 and 2016)

Table Italy Anti-angiogenic Agent Sales by Application (2015 and 2016)

Table Italy Anti-angiogenic Agent Market Share by Application (2015 and 2016)

Figure Spain Anti-angiogenic Agent Sales and Growth Rate (2011-2016)

Figure Spain Anti-angiogenic Agent Revenue and Growth Rate (2011-2016)

Figure Spain Anti-angiogenic Agent Sales Price Trend (2011-2016)

Table Spain Anti-angiogenic Agent Sales by Manufacturers (2015 and 2016)

Table Spain Anti-angiogenic Agent Market Share by Manufacturers (2015 and 2016)

Table Spain Anti-angiogenic Agent Sales by Type (2015 and 2016)

Table Spain Anti-angiogenic Agent Market Share by Type (2015 and 2016)

Table Spain Anti-angiogenic Agent Sales by Application (2015 and 2016)

Table Spain Anti-angiogenic Agent Market Share by Application (2015 and 2016)

Figure Benelux Anti-angiogenic Agent Sales and Growth Rate (2011-2016)

Figure Benelux Anti-angiogenic Agent Revenue and Growth Rate (2011-2016)

Figure Benelux Anti-angiogenic Agent Sales Price Trend (2011-2016)

Table Benelux Anti-angiogenic Agent Sales by Manufacturers (2015 and 2016)

Table Benelux Anti-angiogenic Agent Market Share by Manufacturers (2015 and 2016)

Table Benelux Anti-angiogenic Agent Sales by Type (2015 and 2016)

Table Benelux Anti-angiogenic Agent Market Share by Type (2015 and 2016)

Table Benelux Anti-angiogenic Agent Sales by Application (2015 and 2016)

Table Benelux Anti-angiogenic Agent Market Share by Application (2015 and 2016)

Table Anti-angiogenic Agent Basic Information List

Table Pfizer, Inc. (US) Anti-angiogenic Agent Sales, Revenue, Price and Gross Margin (2011-2016)

Figure Pfizer, Inc. (US) Anti-angiogenic Agent Sales Market Share (2011-2016)

Table Eli Lilly and Company (USA) Basic Information List

Table Eli Lilly and Company (USA) Anti-angiogenic Agent Sales, Revenue, Price and Gross Margin (2011-2016)

Table Eli Lilly and Company (USA) Anti-angiogenic Agent Sales Market Share (2011-2016)

Table Bayer HealthCare Pharmaceuticals, Inc. (USA) Basic Information List

Table Bayer HealthCare Pharmaceuticals, Inc. (USA) Anti-angiogenic Agent Sales, Revenue, Price and Gross Margin (2011-2016)

Table Bayer HealthCare Pharmaceuticals, Inc. (USA) Anti-angiogenic Agent Sales Market Share (2011-2016)

Table Abbott Laboratories (USA) Basic Information List

Table Abbott Laboratories (USA) Anti-angiogenic Agent Sales, Revenue, Price and Gross Margin (2011-2016)

Table Abbott Laboratories (USA) Anti-angiogenic Agent Sales Market Share (2011-2016)

Table AstraZeneca Plc. (UK) Basic Information List

Table AstraZeneca Plc. (UK) Anti-angiogenic Agent Sales, Revenue, Price and Gross Margin (2011-2016)

Table AstraZeneca Plc. (UK) Anti-angiogenic Agent Sales Market Share (2011-2016)

Table Meditrina Pharmaceuticals, Inc. (US) Basic Information List

Table Meditrina Pharmaceuticals, Inc. (US) Anti-angiogenic Agent Sales, Revenue, Price and Gross Margin (2011-2016)

Table Meditrina Pharmaceuticals, Inc. (US) Anti-angiogenic Agent Sales Market Share (2011-2016)

Table Neurocrine Biosciences, Inc. (US) Basic Information List

Table Neurocrine Biosciences, Inc. (US) Anti-angiogenic Agent Sales, Revenue, Price and Gross Margin (2011-2016)

Table Neurocrine Biosciences, Inc. (US) Anti-angiogenic Agent Sales Market Share (2011-2016)

Table AEterna Zentaris, Inc. (Canada) Basic Information List

Table AEterna Zentaris, Inc. (Canada) Anti-angiogenic Agent Sales, Revenue, Price and Gross Margin (2011-2016)

Table AEterna Zentaris, Inc. (Canada) Anti-angiogenic Agent Sales Market Share (2011-2016)

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Anti-angiogenic Agent

Figure Manufacturing Process Analysis of Anti-angiogenic Agent

Figure Anti-angiogenic Agent Industrial Chain Analysis

Table Raw Materials Sources of Anti-angiogenic Agent Major Manufacturers in 2015

Table Major Buyers of Anti-angiogenic Agent

Table Distributors/Traders List

Figure Germany Anti-angiogenic Agent Sales and Growth Rate Forecast (2016-2021)

Figure Germany Anti-angiogenic Agent Revenue and Growth Rate Forecast (2016-2021)

Figure France Anti-angiogenic Agent Sales and Growth Rate Forecast (2016-2021)

Figure France Anti-angiogenic Agent Revenue and Growth Rate Forecast (2016-2021)

Figure UK Anti-angiogenic Agent Sales and Growth Rate Forecast (2016-2021)

Figure UK Anti-angiogenic Agent Revenue and Growth Rate Forecast (2016-2021)

Figure Russia Anti-angiogenic Agent Sales and Growth Rate Forecast (2016-2021)

Figure Russia Anti-angiogenic Agent Revenue and Growth Rate Forecast (2016-2021)

Figure Italy Anti-angiogenic Agent Sales and Growth Rate Forecast (2016-2021)

Figure Italy Anti-angiogenic Agent Revenue and Growth Rate Forecast (2016-2021)

Figure Spain Anti-angiogenic Agent Sales and Growth Rate Forecast (2016-2021)

Figure Spain Anti-angiogenic Agent Revenue and Growth Rate Forecast (2016-2021)

Figure Benelux Anti-angiogenic Agent Sales and Growth Rate Forecast (2016-2021)

Figure Benelux Anti-angiogenic Agent Revenue and Growth Rate Forecast (2016-2021)

Table Europe Anti-angiogenic Agent Sales Forecast by Type (2016-2021)

Table Europe Anti-angiogenic Agent Sales Forecast by Application (2016-2021)

 
Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Contact Us

+ 1-888-961-4454

Drop Us an email at

help@bigmarketresearch.com

Similar Reports

Protein Therapeutics Market by Product (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, and Follicle Stimulating Hormone) and Application (Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...

  • Publish Date: November 14, 2017
  • $5370
Global Cord Blood Banking Services (Stem Cell) Market, Size, Share, Trends, Forecast, Global Analysis, Research, Report, Segmentation, and Future Demand, 2012 - 2020

Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...

  • Publish Date: July 20, 2017
  • $5370